New Diagnosis or Prognosis Biomarkers for Alzheimer's Disease: Biobank of CSF Collected as Part of Differential Diagnosis of Dementia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 50,000
- Locations
- 1
- Primary Endpoint
- CSF collection constitution to have samples available for assessing new Alzheimer's biomarker
Study Overview
Brief Summary
Today, the Alzheimer's disease (AD) diagnosis is founded not only on clinical criteria but also on complementary examinations to confirm a physiopathological process of AD. In complex cases, lumbar punction could be necessary in order to measure Aβ peptides and Total and phosphorylated Tau but new biomarkers could be useful. The main objective of this project is to conserve these cerebrospinal fluids, collected in usual practice in order to validate new biomarkers for diagnosis, prognosis or therapeutic following of Alzheimer's disease and other dementia.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Lumbar punction collected in usual practice in the context of dementia diagnosis
Exclusion Criteria
- •Absence of consent
Outcomes
Primary Outcomes
CSF collection constitution to have samples available for assessing new Alzheimer's biomarker
Time Frame: 50 years
Each CSF collected in the context of dementia diagnosis were conserved to be used in other studies on Alzheimer's or dementia biomarkers. Futre studies that will use collected CSF to assess new biomarkers will be conduced under a new protocol describing scientific contexte, specific aims and time frame necessary to achieve them.
Secondary Outcomes
No secondary outcomes reported
Investigators
Catherine MALAPLATE
MCU-PH
Central Hospital, Nancy, France